Lena Schultz

777 total citations
18 papers, 617 citations indexed

About

Lena Schultz is a scholar working on Pharmacology, Molecular Biology and Oncology. According to data from OpenAlex, Lena Schultz has authored 18 papers receiving a total of 617 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pharmacology, 8 papers in Molecular Biology and 5 papers in Oncology. Recurrent topics in Lena Schultz's work include Inflammatory mediators and NSAID effects (8 papers), Bioactive Compounds and Antitumor Agents (4 papers) and Estrogen and related hormone effects (4 papers). Lena Schultz is often cited by papers focused on Inflammatory mediators and NSAID effects (8 papers), Bioactive Compounds and Antitumor Agents (4 papers) and Estrogen and related hormone effects (4 papers). Lena Schultz collaborates with scholars based in United States, Sweden and United Kingdom. Lena Schultz's co-authors include Ajit Jadhav, Anton Simeonov, David J. Maloney, Theodore R. Holman, Ganesha Rai, Victor Kenyon, Masaaki Sakurai, Steve Perry, Netra Joshi and Udo Oppermann and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Free Radical Biology and Medicine.

In The Last Decade

Lena Schultz

18 papers receiving 606 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lena Schultz United States 11 363 100 99 80 61 18 617
Steve Perry United States 13 337 0.9× 112 1.1× 124 1.3× 123 1.5× 34 0.6× 18 737
Ann‐Kathrin Häfner Germany 14 212 0.6× 85 0.8× 120 1.2× 130 1.6× 30 0.5× 27 503
Netra Joshi United States 7 148 0.4× 62 0.6× 76 0.8× 79 1.0× 17 0.3× 7 366
Richard C. Witt United States 8 221 0.6× 35 0.3× 185 1.9× 57 0.7× 77 1.3× 16 506
Rüdiger Streicher Germany 12 298 0.8× 50 0.5× 60 0.6× 45 0.6× 31 0.5× 17 519
Jessica Roos Germany 13 240 0.7× 54 0.5× 68 0.7× 58 0.7× 51 0.8× 27 435
Sherrill Nurnberg United States 5 229 0.6× 162 1.6× 286 2.9× 74 0.9× 78 1.3× 7 661
Dawn R. Church United States 14 421 1.2× 108 1.1× 83 0.8× 32 0.4× 128 2.1× 23 675
Silvi Luell United States 15 265 0.7× 106 1.1× 54 0.5× 32 0.4× 55 0.9× 21 590

Countries citing papers authored by Lena Schultz

Since Specialization
Citations

This map shows the geographic impact of Lena Schultz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lena Schultz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lena Schultz more than expected).

Fields of papers citing papers by Lena Schultz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lena Schultz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lena Schultz. The network helps show where Lena Schultz may publish in the future.

Co-authorship network of co-authors of Lena Schultz

This figure shows the co-authorship network connecting the top 25 collaborators of Lena Schultz. A scholar is included among the top collaborators of Lena Schultz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lena Schultz. Lena Schultz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Ellmark, Peter, et al.. (2025). First-in-human, multicenter, open-label, phase I study of ATOR-1017 (evunzekibart), a 4-1BB antibody, in patients with advanced solid malignancies. Journal for ImmunoTherapy of Cancer. 13(1). e010113–e010113. 1 indexed citations
2.
Fritzell, Sara, Anneli Nilsson, Karin Barchan, et al.. (2023). ATOR-1017 (evunzekibart), an Fc-gamma receptor conditional 4-1BB agonist designed for optimal safety and efficacy, activates exhausted T cells in combination with anti-PD-1. Cancer Immunology Immunotherapy. 72(12). 4145–4159. 6 indexed citations
3.
Ullenhag, Gustav, et al.. (2022). Initial findings from a first-in-human, multicenter, open-label study of ATOR-1017, a 4-1BB antibody, in patients with advanced solid malignancies.. Journal of Clinical Oncology. 40(16_suppl). 2529–2529. 1 indexed citations
4.
Yachnin, Jeffrey, Gustav Ullenhag, Dorte Nielsen, et al.. (2020). A first-in-human phase I study in patients with advanced and/or refractory solid malignancies to evaluate the safety of ATOR-1015, a CTLA-4 x OX40 bispecific antibody.. Journal of Clinical Oncology. 38(15_suppl). 3061–3061. 7 indexed citations
5.
Kantz, Auric, Lena Schultz, Chakrapani Kalyanaraman, et al.. (2014). A High Throughput Screen Identifies Potent and Selective Inhibitors to Human Epithelial 15-Lipoxygenase-2. PLoS ONE. 9(8). e104094–e104094. 21 indexed citations
6.
Luci, Diane K., Adam Yasgar, Netra Joshi, et al.. (2014). Synthesis and Structure–Activity Relationship Studies of 4-((2-Hydroxy-3-methoxybenzyl)amino)benzenesulfonamide Derivatives as Potent and Selective Inhibitors of 12-Lipoxygenase. Journal of Medicinal Chemistry. 57(2). 495–506. 65 indexed citations
7.
Luci, Diane K., Adam Yasgar, Netra Joshi, et al.. (2014). Discovery of ML355, a Potent and Selective Inhibitor of Human 12-Lipoxygenase. 17 indexed citations
8.
Rai, Ganesha, Netra Joshi, Steve Perry, et al.. (2014). Discovery of ML351, a Potent and Selective Inhibitor of Human 15-Lipoxygenase-1. Europe PMC (PubMed Central). 12 indexed citations
9.
Rai, Ganesha, Netra Joshi, Joo Eun Jung, et al.. (2014). Potent and Selective Inhibitors of Human Reticulocyte 12/15-Lipoxygenase as Anti-Stroke Therapies. Journal of Medicinal Chemistry. 57(10). 4035–4048. 86 indexed citations
10.
Nguyen, Giang Huong, Thomas S. Dexheimer, Andrew S. Rosenthal, et al.. (2013). A Small Molecule Inhibitor of the BLM Helicase Modulates Chromosome Stability in Human Cells. Chemistry & Biology. 20(1). 55–62. 131 indexed citations
11.
Jadhav, Ajit, F. Niesen, Lena Schultz, et al.. (2011). Potent and selective inhibitors of NAD+-dependent 15-hydroxyprostaglandin dehydrogenase (HPGD). 2 indexed citations
12.
Prast‐Nielsen, Stefanie, Thomas S. Dexheimer, Lena Schultz, et al.. (2011). Inhibition of thioredoxin reductase 1 by porphyrins and other small molecules identified by a high-throughput screening assay. Free Radical Biology and Medicine. 50(9). 1114–1123. 29 indexed citations
13.
Kenyon, Victor, Ganesha Rai, Ajit Jadhav, et al.. (2011). Discovery of Potent and Selective Inhibitors of Human Platelet-Type 12- Lipoxygenase. Journal of Medicinal Chemistry. 54(15). 5485–5497. 55 indexed citations
14.
Rai, Ganesha, Ajit Jadhav, Lena Schultz, et al.. (2011). Selective Small Molecule Inhibitors of 12-Human Lipoxygenase (12-hLO). 2 indexed citations
15.
Nangia, Chaitali, et al.. (2011). The role of the development of hypertension or proteinuria in predicting outcome with the use of bevacizumab for patients with glioblastoma multiforme (GBM).. Journal of Clinical Oncology. 29(15_suppl). 2021–2021. 8 indexed citations
16.
Niesen, F., Lena Schultz, Ajit Jadhav, et al.. (2010). High-Affinity Inhibitors of Human NAD+-Dependent 15-Hydroxyprostaglandin Dehydrogenase: Mechanisms of Inhibition and Structure-Activity Relationships. PLoS ONE. 5(11). e13719–e13719. 29 indexed citations
17.
Rai, Ganesha, Victor Kenyon, Ajit Jadhav, et al.. (2010). Discovery of Potent and Selective Inhibitors of Human Reticulocyte 15-Lipoxygenase-1. Journal of Medicinal Chemistry. 53(20). 7392–7404. 69 indexed citations
18.
Sakurai, Masaaki, Nathan R. Rose, Lena Schultz, et al.. (2009). A miniaturized screen for inhibitors of Jumonji histonedemethylases. Molecular BioSystems. 6(2). 357–364. 76 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Steve Perry Breakdown of academic impact, for papers by Ann‐Kathrin Häfner Breakdown of academic impact, for papers by Netra Joshi Breakdown of academic impact, for papers by Richard C. Witt Breakdown of academic impact, for papers by Rüdiger Streicher Breakdown of academic impact, for papers by Jessica Roos Breakdown of academic impact, for papers by Sherrill Nurnberg Breakdown of academic impact, for papers by Dawn R. Church Breakdown of academic impact, for papers by Silvi Luell
Rankless by CCL
2026